BioCentury
ARTICLE | Clinical News

MC2's non-greasy psoriasis cream superior to Taclonex

August 21, 2018 7:52 AM UTC

MC2 Therapeutics A/S (Horsholm, Denmark) said MC2-01, its non-greasy topical cream formulation of calcipotriene/betamethasone dipropionate, was superior to Taclonex, a marketed formulation of the combination, on the primary and secondary endpoints in a Phase III trial to treat mild to moderate psoriasis. MC2 plans to submit an NDA to FDA in 1H19 for MC2-01, its lead candidate, which uses the company’s PAD technology.

MC2 said marketed formulations of calcipotriene/betamethasone are greasy or liquid oil formulations that patients do not like to use, leading to low compliance and poor efficacy. MC2’s PAD vehicles are oil-in-water dispersions that use an aqueous film of surfactants to encapsulate the oil phase, resulting in a stable cream formulation of calcipotriene/betamethasone that is quickly absorbed into the skin and allows patients to continue on with their daily routines...